Summary
An ongoing trial of combination chemotherapy using ifosfamide (Holoxan), epirubicin and 5-fluorouracil was started in 1987. A total of 30 patients with metastatic cancer of the breast received 1.5 g/m2 i. v. ifosfamide over 60 min on days 1–3, 50 mg/m2 i. v. epirubicin on day 1 and 500 mg/m2 i. v. 5-fluorouracil on day 1, followed by mesna (Uromitexan) given at 20% of the ifosfamide dose at 0, 4 and 8 h. The courses were repeated every 4 weeks. In all, 198 courses were given, ranging from 3 to 13 (median, 7) cycles/patient. The mean age of the 30 patients was 48 years (range, 35–66 years); 5 had not previously received chemotherapy and the others had failed prior cytotoxic and endocrine therapy. Overall, 28 patients were evaluable, 7 (25%) showed a complete response and 15 (54%) had a partial response, for an overall response rate of 22/28 (79%). Three patients showed stable disease with improved symptoms, and in three cases disease progression occurred. The median duration of response was 9 months (range, 3–20 months). Median survival was 11 months for all patients, 15 months for CRs, 10 months for PRs, 6 months for stable disease and 12 months for progressive disease (PD). Survival for the 22 responding patients was 12 months. Toxicity was acceptable and included alopecia, mucositis, nausea, vomiting, diarrhoea, mild cystitis and myelosuppression. Epirubicin did not appear to produce cardiac toxicity, and ifosfamide with mesna did not seem to result in severe urotoxicity. Chemotherapy with ifosfamide, epirubicin and 5-fluorouracil proved to be effective for treatment of advanced breast cancer and should be further studied in large, controlled trials.
Similar content being viewed by others
References
Bonadona G (1984) In: Advances in anthracycline chemotherapy: epirubicin, 1st edn. Masson, Milano, p 193
Brade WP, Herdrich K, Varini M (1985) Ifosfamide-pharmacology, safety and therapeutic potential. Cancer Treat Rev 12: 1
Buzdar AU, Legha SS, Tashima CK, Yap H-Y, Hortobagyi GN, Hersh EM, Blumenschein GR, Bodey GP (1979) Ifosfamide versus cyclophosphamide in combination drug therapy for metastatic breast cancer. Cancer Treat Rep 63: 115
Keiling R, Armand PP, Hourteloup P, Cappelaere P (1986) Die französische FAC vs. FEC-Studie bei fortgeschrittenen Mammakarzinomen. Onkologie 9 [Suppl 1]: 8
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ghavamzadeh, A. Treatment of metastatic breast cancer with the combination of ifosfamide, epirubicin and 5-fluorouracil. Cancer Chemother. Pharmacol. 26 (Suppl 1), S66–S68 (1990). https://doi.org/10.1007/BF00685424
Issue Date:
DOI: https://doi.org/10.1007/BF00685424